CA2574991C - Methods for diagnosis of appendicitis - Google Patents
Methods for diagnosis of appendicitis Download PDFInfo
- Publication number
- CA2574991C CA2574991C CA2574991A CA2574991A CA2574991C CA 2574991 C CA2574991 C CA 2574991C CA 2574991 A CA2574991 A CA 2574991A CA 2574991 A CA2574991 A CA 2574991A CA 2574991 C CA2574991 C CA 2574991C
- Authority
- CA
- Canada
- Prior art keywords
- appendicitis
- mrp
- sample
- protein
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010003011 Appendicitis Diseases 0.000 title claims abstract description 223
- 238000000034 method Methods 0.000 title claims abstract description 72
- 238000003745 diagnosis Methods 0.000 title description 16
- 102000018803 Calgranulin A Human genes 0.000 claims abstract description 84
- 108010052500 Calgranulin A Proteins 0.000 claims abstract description 84
- 102000014702 Haptoglobin Human genes 0.000 claims abstract description 28
- 108050005077 Haptoglobin Proteins 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 16
- 238000003556 assay Methods 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 210000002966 serum Anatomy 0.000 claims description 33
- 208000002193 Pain Diseases 0.000 claims description 19
- 230000036407 pain Effects 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 14
- 210000001015 abdomen Anatomy 0.000 claims description 11
- 210000003097 mucus Anatomy 0.000 claims description 9
- 206010047700 Vomiting Diseases 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 8
- 230000008673 vomiting Effects 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 238000010324 immunological assay Methods 0.000 claims description 4
- 206010024378 leukocytosis Diseases 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 3
- 208000021760 high fever Diseases 0.000 claims description 3
- 208000030208 low-grade fever Diseases 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010057071 Rectal tenesmus Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000032140 Sleepiness Diseases 0.000 claims description 2
- 206010041349 Somnolence Diseases 0.000 claims description 2
- 208000020560 abdominal swelling Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 230000037321 sleepiness Effects 0.000 claims description 2
- 208000012271 tenesmus Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 23
- 239000012530 fluid Substances 0.000 abstract description 11
- 238000003018 immunoassay Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 48
- 230000004054 inflammatory process Effects 0.000 description 17
- 238000001262 western blot Methods 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 108010052495 Calgranulin B Proteins 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 102100032420 Protein S100-A9 Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 206010000060 Abdominal distension Diseases 0.000 description 8
- 238000007486 appendectomy Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 5
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 238000001155 isoelectric focusing Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000000575 proteomic method Methods 0.000 description 5
- 206010056988 Faecalith Diseases 0.000 description 4
- 208000008415 Fecal Impaction Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 3
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000008952 bacterial invasion Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010060921 Abdominal abscess Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 102000018755 Calgranulin B Human genes 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 238000009557 abdominal ultrasonography Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003012 Appendicitis perforated Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 240000007591 Tilia tomentosa Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000742 appendix Anatomy 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 108010071602 haptoglobin-hemoglobin complex Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- XGFJCRNRWOXGQM-UHFFFAOYSA-N hot-2 Chemical compound CCSC1=CC(OC)=C(CCNO)C=C1OC XGFJCRNRWOXGQM-UHFFFAOYSA-N 0.000 description 1
- 102000051258 human S100A8 Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000505 parietal peritoneum Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000009024 positive feedback mechanism Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004760 visceral afferent Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59063104P | 2004-07-23 | 2004-07-23 | |
| US60/590,631 | 2004-07-23 | ||
| PCT/US2005/026218 WO2006012588A2 (en) | 2004-07-23 | 2005-07-25 | Methods and devices for diagnosis of appendicitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2574991A1 CA2574991A1 (en) | 2006-02-02 |
| CA2574991C true CA2574991C (en) | 2015-03-24 |
Family
ID=35786760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2574991A Expired - Fee Related CA2574991C (en) | 2004-07-23 | 2005-07-25 | Methods for diagnosis of appendicitis |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7501256B2 (https=) |
| EP (2) | EP2258866A3 (https=) |
| JP (3) | JP4447641B2 (https=) |
| KR (1) | KR20070051287A (https=) |
| CN (1) | CN101124336A (https=) |
| AT (1) | ATE494391T1 (https=) |
| AU (1) | AU2005266921B2 (https=) |
| BR (1) | BRPI0513740A (https=) |
| CA (1) | CA2574991C (https=) |
| DE (1) | DE602005025775D1 (https=) |
| EA (1) | EA200700351A1 (https=) |
| ES (1) | ES2359822T3 (https=) |
| IL (1) | IL180784A (https=) |
| MX (1) | MX2007000956A (https=) |
| NO (1) | NO20071015L (https=) |
| NZ (2) | NZ553386A (https=) |
| SG (1) | SG150497A1 (https=) |
| TR (1) | TR200700896T1 (https=) |
| WO (1) | WO2006012588A2 (https=) |
| ZA (1) | ZA200701450B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005025775D1 (de) | 2004-07-23 | 2011-02-17 | Aspenbio Pharma Inc | Verfahren und vorrichtungen zur diagnose von appendizitis |
| US7659087B2 (en) * | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
| DE602007007209D1 (de) * | 2006-05-19 | 2010-07-29 | Roche Diagnostics Gmbh | Verwendung des proteins s100a 12 als marker für kolorektalkarzinom |
| EP2350646B1 (en) * | 2008-10-28 | 2016-01-13 | Assistance Publique - Hôpitaux de Paris | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
| EP2382466B1 (en) | 2008-12-30 | 2016-03-09 | Children's Medical Center Corporation | Method of predicting acute appendicitis |
| US8541187B2 (en) | 2011-03-01 | 2013-09-24 | Bio Tracking, LLC | Systems and methods for detecting animal pregnancy |
| RU2477071C1 (ru) * | 2011-11-07 | 2013-03-10 | Федеральное государственное бюджетное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Сибирского отделения Российской академии медицинских наук | Способ диагностики острого аппендицита у детей |
| CA2856213A1 (en) * | 2011-11-16 | 2013-05-23 | Venaxis, Inc. | Compositions and methods for assessing appendicitis |
| CN105556308B (zh) * | 2013-09-20 | 2018-05-29 | 阿斯图特医药公司 | 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物 |
| WO2015159239A1 (en) * | 2014-04-15 | 2015-10-22 | Stellenbosch University | A method for diagnosing tuberculous meningitis |
| EP3553524A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Periodontitis diagnostic methods, uses and kits |
| WO2020241617A1 (ja) * | 2019-05-29 | 2020-12-03 | 富士フイルム和光純薬株式会社 | 抗ヒトハプトグロビン抗体、及びこれを用いた炎症性腸疾患の判定方法 |
| CN112578125B (zh) * | 2019-09-27 | 2022-10-25 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备卵巢病变筛查试剂盒中的用途 |
| JP7509361B2 (ja) * | 2020-07-22 | 2024-07-02 | 富士フイルム株式会社 | 炎症性腸疾患の診断を補助する方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US175754A (en) * | 1876-04-04 | Improvement in pen-holdjng pencil-point protectors | ||
| US241775A (en) * | 1881-05-24 | Water-meter | ||
| US95249A (en) * | 1869-09-28 | Improvement in presses | ||
| US224452A (en) * | 1880-02-10 | Uterine supporter | ||
| US121343A (en) * | 1871-11-28 | Improvement in machines for blacking boots and shoes | ||
| US249003A (en) * | 1881-11-01 | Wrench | ||
| US24719A (en) * | 1859-07-12 | Hanging bodies of vehicles | ||
| US155813A (en) * | 1874-10-13 | Improvement in buckles | ||
| US136588A (en) * | 1873-03-11 | Improvement in vessels for steaming oysters | ||
| DE3032108A1 (de) | 1980-08-22 | 1982-04-01 | Andreas Dr.-Ing. 1000 Berlin Hampe | Messanordnung zum ermitteln der wirksamkeit eines erdwaermegewinnung im erdreich angeordneten waermetauscherelements |
| GB8318754D0 (en) * | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| ES2052602T3 (es) | 1986-10-03 | 1994-07-16 | Ciba Geigy Ag | Nuevos peptidos afines a las linfocinas. |
| US5055389A (en) * | 1987-08-12 | 1991-10-08 | Appenditech, Inc. | Detection of appendicitis by measurement of uroerythrin |
| CA2008414A1 (en) * | 1989-11-15 | 1991-05-15 | David Bar-Or | Detection of appendicits by measurement of ortho-hydroxyhippuric acid |
| CH685959A5 (de) | 1992-08-24 | 1995-11-15 | Biomedicals Ag | Diagnostische Testpackung zur Bestimmung von Proteinen. |
| US5455160A (en) * | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| US5552295A (en) | 1994-03-02 | 1996-09-03 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to bovine haptoglobin and methods for detecting serum haptoglobin levels |
| DE69837529T2 (de) * | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| GB9723773D0 (en) | 1997-11-12 | 1998-01-07 | Univ Glasgow | Haptoglobin assay |
| DE69941627D1 (de) | 1998-11-05 | 2009-12-17 | Univ Michigan | Für krebs |
| SE0001932D0 (sv) * | 2000-05-24 | 2000-05-24 | David Sandahl | Anordning för dämpning av ryck |
| US6749565B2 (en) | 2000-07-08 | 2004-06-15 | Victor Chudner | Method for blood infrared spectroscopy diagnosing of inner organs pathology |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| TW583354B (en) * | 2001-05-25 | 2004-04-11 | Mitsui Shipbuilding Eng | Method for producing amorphous SiC wafer |
| WO2003069349A2 (en) | 2002-02-15 | 2003-08-21 | Clemens Sorg | Method for diagnosis of inflammatory diseases using mrp8/mrp14 |
| EP1546716A4 (en) | 2002-05-02 | 2007-04-11 | Aspenbio Inc | PREGNANCY PROOF |
| EP1587409B1 (en) | 2002-10-09 | 2013-01-16 | DMI Biosciences, Inc. | Diagnosis and monitoring of acute coronary syndrome |
| JP2006511790A (ja) * | 2002-11-14 | 2006-04-06 | サイファージェン バイオシステムズ インコーポレイテッド | 羊膜内炎症のためのバイオマーカー |
| GB0229747D0 (en) | 2002-12-20 | 2003-01-29 | Axis Shield Asa | Assay |
| WO2004059293A2 (en) | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| DE602005025775D1 (de) * | 2004-07-23 | 2011-02-17 | Aspenbio Pharma Inc | Verfahren und vorrichtungen zur diagnose von appendizitis |
| US7659087B2 (en) | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
| JP2006177679A (ja) | 2004-12-20 | 2006-07-06 | Keio Gijuku | 診断マーカー及び薬効マーカー、並びにそれらの利用方法 |
| JP2006256140A (ja) | 2005-03-17 | 2006-09-28 | Ricoh Co Ltd | 画像形成装置 |
-
2005
- 2005-07-25 DE DE602005025775T patent/DE602005025775D1/de not_active Expired - Lifetime
- 2005-07-25 SG SG200900812-9A patent/SG150497A1/en unknown
- 2005-07-25 EP EP10007673A patent/EP2258866A3/en not_active Withdrawn
- 2005-07-25 JP JP2007522830A patent/JP4447641B2/ja not_active Expired - Fee Related
- 2005-07-25 AT AT05775574T patent/ATE494391T1/de not_active IP Right Cessation
- 2005-07-25 EA EA200700351A patent/EA200700351A1/ru unknown
- 2005-07-25 KR KR1020077004381A patent/KR20070051287A/ko not_active Ceased
- 2005-07-25 ES ES05775574T patent/ES2359822T3/es not_active Expired - Lifetime
- 2005-07-25 WO PCT/US2005/026218 patent/WO2006012588A2/en not_active Ceased
- 2005-07-25 NZ NZ553386A patent/NZ553386A/en not_active IP Right Cessation
- 2005-07-25 NZ NZ580805A patent/NZ580805A/en not_active IP Right Cessation
- 2005-07-25 EP EP05775574A patent/EP1778869B9/en not_active Expired - Lifetime
- 2005-07-25 TR TR2007/00896T patent/TR200700896T1/xx unknown
- 2005-07-25 AU AU2005266921A patent/AU2005266921B2/en not_active Ceased
- 2005-07-25 CN CNA2005800312784A patent/CN101124336A/zh active Pending
- 2005-07-25 US US11/189,120 patent/US7501256B2/en not_active Expired - Fee Related
- 2005-07-25 CA CA2574991A patent/CA2574991C/en not_active Expired - Fee Related
- 2005-07-25 MX MX2007000956A patent/MX2007000956A/es not_active Application Discontinuation
- 2005-07-25 BR BRPI0513740-3A patent/BRPI0513740A/pt not_active Application Discontinuation
-
2007
- 2007-01-18 IL IL180784A patent/IL180784A/en active IP Right Grant
- 2007-02-19 ZA ZA200701450A patent/ZA200701450B/xx unknown
- 2007-02-22 NO NO20071015A patent/NO20071015L/no not_active Application Discontinuation
-
2009
- 2009-02-11 US US12/369,640 patent/US7670789B2/en not_active Expired - Fee Related
- 2009-06-26 JP JP2009153020A patent/JP4486153B2/ja not_active Expired - Fee Related
- 2009-12-08 JP JP2009278989A patent/JP2010054519A/ja not_active Withdrawn
-
2010
- 2010-01-20 US US12/690,567 patent/US20100184070A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7670789B2 (en) | Methods and devices for diagnosis of appendicitis | |
| US7659087B2 (en) | Methods and devices for diagnosis of appendicitis | |
| Costa et al. | Role of faecal calprotectin as non-invasive marker of intestinal inflammation | |
| Hedstöm et al. | Urinary trypsinogen-2 test strip for acute pancreatitis | |
| US8163501B2 (en) | Methods of assessing Crohn's disease patient phenotype by I2 serologic response | |
| Cenni et al. | The use of calgranulin-C (S100A12) and fecal zonulin as possible non-invasive markers in children with inflammatory bowel disease: A clinical study | |
| CN117783534A (zh) | 一种乳腺癌分子标志物及其应用 | |
| HK1102830B (en) | Methods and devices for diagnosis of appendicitis | |
| EP1613960B1 (en) | Methods of assessing crohn's disease patient phenotype by i2, ompc and asca serologic response | |
| US20200141949A1 (en) | Use of the rho gdp dissociation inhibitor 2 protein as a diagnostic and prognostic marker of intestinal inflammatory diseases | |
| HK1141836A (en) | Methods and devices for diagnosis of appendicitis | |
| WO2019016753A1 (en) | USE OF GELSOLIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INTESTINAL INFLAMMATORY DISEASES | |
| Öztürk | Diagnostic Significance of Chemerin and Chitinase 3-Like Protein 1 Levels in Cholelithiasis | |
| Tudoroniu et al. | New Metabolic and Genetic Biomarkers for Diagnosis of Ulcerative Colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170725 |